New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational…
Global Specialty Chemicals Leader Chooses Kneat for Digital Validation
Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards